Get the Stockscreener App
27.38
0.65%
-0.18
Structure Therapeutics Inc Adr stock is traded at $27.38, with a volume of 510.86K.
It is down -0.65% in the last 24 hours and up +26.47% over the past month.
Structure Therapeutics Inc is a clinical-stage biopharmaceutical company developing novel oral small-molecule therapeutics to treat a wide range of chronic diseases with unmet medical needs. Its differentiated technology platform leverages both structure-based drug discovery and expertise in computational chemistry to discover and develop small molecule therapeutics against G-protein coupled receptors (GPCRs). The group operates and manages its business as one reportable and operating segment, which is the business of research and development of medicines that target chronic diseases with unmet medical needs.
See More
Previous Close:
$27.56
Open:
$27.06
24h Volume:
510.86K
Relative Volume:
0.50
Market Cap:
$1.58B
Revenue:
-
Net Income/Loss:
$-100.44M
P/E Ratio:
-12.33
EPS:
-2.22
Net Cash Flow:
$-105.32M
1W Performance:
-8.95%
1M Performance:
+26.47%
6M Performance:
+25.83%
1Y Performance:
-30.89%
1-Day Range:
$27.00
$28.56
1-Week Range:
$27.00
$31.08
52-Week Range:
$13.22
$42.57
Structure Therapeutics Inc Adr Stock (GPCR) Company Profile
Name
Structure Therapeutics Inc Adr
Sector
Industry
Phone
(628) 229-9277
Address
611 GATEWAY BLVD SUITE 223, SOUTH SAN FRANCISCO
Compare GPCR with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
GPCR
Structure Therapeutics Inc Adr
|
27.38 | 1.59B | 0 | -100.44M | -105.32M | -2.22 |
|
VRTX
Vertex Pharmaceuticals Inc
|
416.81 | 104.76B | 11.39B | 3.64B | 3.50B | 13.99 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
481.67 | 63.06B | 2.46B | -319.09M | -52.09M | -2.4669 |
|
REGN
Regeneron Pharmaceuticals Inc
|
578.05 | 60.32B | 14.21B | 4.46B | 3.56B | 39.69 |
|
ARGX
Argen X Se Adr
|
843.66 | 51.55B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
165.76 | 34.49B | 398.11M | -1.03B | -868.57M | -5.7032 |
Structure Therapeutics Inc Adr Stock (GPCR) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| May-02-25 | Initiated | Citigroup | Buy |
| Feb-28-25 | Initiated | William Blair | Outperform |
| Jan-08-25 | Initiated | Stifel | Buy |
| Dec-04-24 | Initiated | H.C. Wainwright | Buy |
| Sep-23-24 | Initiated | Morgan Stanley | Overweight |
| May-21-24 | Initiated | JP Morgan | Overweight |
| Apr-09-24 | Initiated | Cantor Fitzgerald | Overweight |
| Oct-19-23 | Initiated | JMP Securities | Mkt Outperform |
| Jul-27-23 | Initiated | Piper Sandler | Overweight |
| May-25-23 | Resumed | Jefferies | Buy |
| Feb-28-23 | Initiated | BMO Capital Markets | Outperform |
| Feb-28-23 | Initiated | Guggenheim | Buy |
| Feb-28-23 | Initiated | Jefferies | Buy |
| Feb-28-23 | Initiated | SVB Securities | Outperform |
View All
Structure Therapeutics Inc Adr Stock (GPCR) Latest News
Analysts Offer Insights on Healthcare Companies: Bristol-Myers Squibb (BMY) and Aclaris Therapeutics (ACRS) - The Globe and Mail
Analysts Set Structure Therapeutics Inc. Sponsored ADR (NASDAQ:GPCR) Target Price at $68.67 - Defense World
Brokerages Set Structure Therapeutics Inc. Sponsored ADR (NASDAQ:GPCR) PT at $68.67 - Defense World
Structure Therapeutics Inc. Sponsored ADR (NASDAQ:GPCR) Receives Consensus Recommendation of "Moderate Buy" from Brokerages - MarketBeat
Structure Therapeutics Inc. Sponsored ADR (NASDAQ:GPCR) Receives Average Rating of "Moderate Buy" from Analysts - MarketBeat
Structure Therapeutics' (GPCR) "Sell (D-)" Rating Reaffirmed at Weiss Ratings - MarketBeat
Structure Therapeutics Inc. Sponsored ADR $GPCR Shares Purchased by Signaturefd LLC - Defense World
Piper Sandler Keeps Their Buy Rating on Structure Therapeutics, Inc. Sponsored ADR (GPCR) - The Globe and Mail
Layoff Tracker: CSL Vifor, Bolt Cut Staff - BioSpace
Citius Oncology (NASDAQ:CTOR) and Structure Therapeutics (NASDAQ:GPCR) Head to Head Survey - Defense World
Structure Therapeutics (NASDAQ:GPCR) Trading Down 4.3%Should You Sell? - MarketBeat
ABSSSI Market to Reach New Heights in Growth by 2034, DelveInsight Predicts | Glenmark Pharma, Melinta Therapeutics, Sandoz Inc, Paratek Pharma, AbbVie Inc., Allergan PLC, Merck & Co. Inc., Pfizer - The Globe and Mail
ABSSSI Market to Reach New Heights in Growth by 2034, - openPR.com
Structure Therapeutics (NASDAQ:GPCR) Trading 5.8% HigherTime to Buy? - MarketBeat
ETFs Investing in Structure Therapeutics, Inc. Sponsored ADR Stocks - TradingView
Lunai Bioworks Unveils New Corporate Identity, Streamlined Capital Structure, and Strategic Focus on AI-Powered Therapeutics and Biodefense - The Globe and Mail
Banque Pictet & Cie SA Sells 11,365 Shares of Structure Therapeutics Inc. Sponsored ADR $GPCR - MarketBeat
Structure Therapeutics stock rating reiterated at Buy by H.C. Wainwright - Investing.com India
Interactive Brokers Group, Inc. $IBKR Shares Acquired by Swedbank AB - Defense World
Sumitomo Mitsui DS Asset Management Company Ltd Makes New Investment in Confluent, Inc. $CFLT - Defense World
Exchange Traded Concepts LLC Buys 1,054 Shares of TKO Group Holdings, Inc. $TKO - Defense World
IFM Investors Pty Ltd Has $3.42 Million Stock Position in Annaly Capital Management Inc $NLY - Defense World
MongoDB, Inc. $MDB Shares Acquired by IFM Investors Pty Ltd - Defense World
Wealth Enhancement Advisory Services LLC Grows Stock Holdings in VanEck Semiconductor ETF $SMH - Defense World
Voya Investment Management LLC Buys 1,696 Shares of PriceSmart, Inc. $PSMT - Defense World
Voya Investment Management LLC Lowers Stock Position in Dutch Bros Inc. $BROS - Defense World
Vanguard Total International Bond ETF $BNDX Shares Bought by Exchange Traded Concepts LLC - Defense World
IFM Investors Pty Ltd Boosts Position in Evergy Inc. $EVRG - Defense World
IFM Investors Pty Ltd Grows Holdings in Trimble Inc. $TRMB - Defense World
UnitedHealth Group Incorporated $UNH Shares Acquired by Exchange Traded Concepts LLC - Defense World
DNOW Inc. $DNOW Shares Purchased by Exchange Traded Concepts LLC - Defense World
Exchange Traded Concepts LLC Purchases 22,809 Shares of Structure Therapeutics Inc. Sponsored ADR $GPCR - Defense World
IFM Investors Pty Ltd Purchases 2,676 Shares of Deckers Outdoor Corporation $DECK - Defense World
Exchange Traded Concepts LLC Has $1.14 Million Holdings in Molina Healthcare, Inc $MOH - Defense World
Exchange Traded Concepts LLC Acquires New Holdings in Vanguard Total Stock Market ETF $VTI - Defense World
Pallas Capital Advisors LLC Buys New Shares in Keysight Technologies Inc. $KEYS - Defense World
Parallel Advisors LLC Takes $171,000 Position in Structure Therapeutics Inc. Sponsored ADR $GPCR - Defense World
BICO Group AB (publ) (OTCMKTS:CLLKF) Stock Price Down 10.2% – Should You Sell? - Defense World
Structure Therapeutics (NASDAQ:GPCR) Shares Gap UpShould You Buy? - MarketBeat
Biotech Stocks Moving Premarket: QLGN, MBX, HSDT, And Other Gainers & Losers - RTTNews
iShares U.S. Insurance ETF $IAK Shares Sold by Focus Financial Network Inc. - Defense World
xFOREST Therapeutics and Axcelead DDP Launch Joint Research Initiative on RNA Structure-Targeted Small Molecule Drug Discovery - BioSpace
Structure Therapeutics Inc. (GPCR) Eyes Major 2025 Catalyst With Phase 2b Obesity Data - Insider Monkey
Relay Therapeutics, Inc. (RLAY) Shows Breakthrough Breast Cancer Results With RLY-2608 - Yahoo Finance
Structure Therapeutics (NASDAQ:GPCR) Trading 6.3% HigherHere's What Happened - MarketBeat
Structure Therapeutics Inc. Sponsored ADR (NASDAQ:GPCR) Receives $75.71 Average Price Target from Brokerages - MarketBeat
Analysts Are Bullish on These Healthcare Stocks: Scholar Rock Holding (SRRK), Akero Therapeutics (AKRO) - The Globe and Mail
Top 10 AI-Powered Biotech Stocks to Buy Now - Insider Monkey
Promising Market Potential for Structure Therapeutics: Buy Rating Backed by Superior Trial Results and Market Opportunities - TipRanks
Structure Therapeutics stock rating reiterated by Cantor Fitzgerald - Investing.com
Structure Therapeutics stock rating reiterated by JMP, citing positive safety data - Investing.com
Structure Therapeutics Inc Adr Stock (GPCR) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.84%
0.50%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):